イピリムマブ (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "イピリムマブ" in Japanese language version.

refsWebsite

Global rank Japanese rank

14nih.gov

4^th place

24^th place

8doi.org

2^nd place

6^th place

4clinicaltrials.gov

5,225^th place

low place

4google.co.jp

934^th place

57^th place

3wikipedia.org

low place

3bms.com

low place

2nytimes.com

7^th place

63^rd place

2reuters.com

49^th place

67^th place

1bms.co.jp

low place

1novapublishers.com

low place

1nikkeibp.co.jp

1,415^th place

95^th place

1carenet.com

low place

1fda.gov

447^th place

1,043^rd place

1drugs.com

399^th place

1,603^rd place

1hc-sc.gc.ca

low place

1genengnews.com

low place

1sanofi.com.au

low place

1oclc.org

1,391^st place

7,217^th place

1gene.com

low place

1europa.eu

68^th place

425^th place

1rupress.org

low place

1sciencemag.org

857^th place

1,005^th place

1healthvalue.net

low place

1web.archive.org

1^st place

1forbes.com

54^th place

269^th place

1news-medical.net

8,069^th place

low place

1pharmalot.com

low place

1bbc.co.uk

8^th place

73^rd place

1mayoclinic.org

1,610^th place

7,929^th place

1webmd.com

1,169^th place

1,632^nd place

1corante.com

low place

1jrs.or.jp

low place

3,712^th place

1peregrineinc.com

low place

bbc.co.uk

news.bbc.co.uk

“'Surprise' prostate result probed”. BBC News. (2009年6月19日) 2009年6月24日閲覧。

bms.co.jp

“YERVOY™（一般名：ipilimumab）、新たに診断されたまたは、前治療歴のある切除不能または転移性悪性黒色腫（メラノーマ）の患者の治療薬として、FDAの承認を取得”. ブリストル・マイヤーズ (2011年3月31日). 2015年7月9日閲覧。

bms.com

news.bms.com

"Bristol-Myers Squibb Receives Positive Decision from National Institute of Health and Clinical Excellence (NICE) for YERVOY (ipilimumab)" (Press release). 1 November 2012. 2012年12月17日閲覧。
“Top-Line Data Available from Three Ipilimumab Pivotal Trials in Patients with Advanced Metastatic Melanoma”. Medarex, Inc. (2007年12月10日). 2015年7月9日閲覧。

packageinserts.bms.com

“Yervoy (ipilimumab) [package insert]”. Princeton, NJ: Bristol-Myers Squibb Company; Dec 2013. 2014年10月29日閲覧。

carenet.com

“抗CTLA-4抗体イピリムマブが悪性黒色腫に承認”. ケアネット (2015年7月8日). 2015年7月9日閲覧。

clinicaltrials.gov

臨床試験番号 NCT00527735 - ClinicalTrials.gov Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)
臨床試験番号 NCT01524991 - ClinicalTrials.gov
臨床試験番号 NCT00323882 - ClinicalTrials.gov Phase I/II Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer (MDX010-21) (COMPLETED)
“A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients”. ClinicalTrials.gov. 2015年7月9日閲覧。

corante.com

pipeline.corante.com

Lowe D (2009年6月23日). “Medarex, Ipilimumab, Prostate Cancer, And Reality. :”. Corante. 2009年6月24日閲覧。

doi.org

Antoni Ribas (28 June 2012). “Tumor immunotherapy directed at PD-1”. New England Journal of Medicine 366 (26): 2517–9. doi:10.1056/nejme1205943.
Maverakis E, Cornelius LA, Bowen GM, Phan T, Patel FB, Fitzmaurice S, He Y, Burrall B, Duong C, Kloxin AM, Sultani H, Wilken R, Martinez SR, Patel F (2015). “Metastatic melanoma - a review of current and future treatment options”. Acta Derm Venereol 95 (5): 516-524. doi:10.2340/00015555-2035. PMID 25520039.
Ribas, Antoni; Hodi, F. Stephen; Callahan, Margaret; Konto, Cyril; Wolchok, Jedd (April 4, 2013). “Hepatotoxicity with combination of vemurafenib and ipilimumab”. N Engl J Med 368 (14): 1365-6. doi:10.1056/NEJMc1302338. PMID 23550685 2014年10月29日閲覧。.
Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S (2000). “Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.”. J Exp Med. 192 (2): 303-10. doi:10.1084/jem.192.2.303. PMC 2193248. PMID 10899917.
Tarhini AA, Iqbal F (2010). “CTLA-4 blockade: therapeutic potential in cancer treatments”. Onco Targets Ther 3: 15–25. doi:10.2147/ott.s4833. PMC 2895779. PMID 20616954.
Robert C, Ghiringhelli F (August 2009). “What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?”. Oncologist 14 (8): 848–61. doi:10.1634/theoncologist.2009-0028. PMID 19648604.
Sharma, Pamanee; Allison, James P. (April 3, 2015). “The future of immune checkpoint therapy”. Science. doi:10.1126/science.aaa8172 2015年6月閲覧。エラー: 閲覧日は年・月・日のすべてを記入してください。.
Poust J (December 2008). “Targeting metastatic melanoma”. Am J Health Syst Pharm 65 (24 Suppl 9): S9–S15. doi:10.2146/ajhp080461. PMID 19052265.

drugs.com

Drugs.com: Yervoy

europa.eu

ema.europa.eu

“Yervoy Annex I: Summary of Product Characteristics”. 2014年11月2日閲覧。

fda.gov

Jefferson E (25 March 2011). "FDA approves new treatment for a type of late-stage skin cancer" (Press release). U.S. Food and Drug Administration (FDA). 2011年3月25日閲覧。^{[リンク切れ]}

forbes.com

blogs.forbes.com

Langreth R (2010年6月6日). “The Risk For Bristol”. Science Business - research, innovation & policy. Forbes. 2011年7月22日時点のオリジナルよりアーカイブ。2011年3月25日閲覧。

gene.com

“Zelboraf (vemurafenib) [package insert]”. South San Francisco, CA: Genentech USA, Inc.; March 2013. 2014年10月29日閲覧。

genengnews.com

“FDA Rubber-Stamps Bristol-Myers Squibb’s Melanoma mAb”. Genetic Engineering & Biotechnology News (2011年3月28日). 2011年3月28日閲覧。

google.co.jp

books.google.co.jp

Gail M. Wilkes; Margaret Barton-Burke (11 December 2009). 2010 oncology nursing drug handbook. Jones & Bartlett Learning. pp. 1–. ISBN 978-0-7637-8124-8 2011年3月30日閲覧。
L. Harivardhan Reddy; Patrick Couvreur (1 June 2009). Macromolecular Anticancer Therapeutics. Springer. pp. 522–. ISBN 978-1-4419-0506-2 2011年3月30日閲覧。
Zhiqiang An (8 September 2009). Therapeutic Monoclonal Antibodies: From Bench to Clinic. John Wiley and Sons. pp. 134–. ISBN 978-0-470-11791-0 2011年3月30日閲覧。
Ralph Blum; Mark Scholz (24 August 2010). Invasion of the Prostate Snatchers: No More Unnecessary Biopsies, Radical Treatment Or Loss of Sexual Potency. Other Press, LLC. pp. 227–. ISBN 978-1-59051-342-2 2011年3月30日閲覧。

hc-sc.gc.ca

Notice of Decision for YERVOY^{[リンク切れ]}

healthvalue.net

“CTLA-4 strategies: Abatacept / Belatacept”. healthvalue.net. 2009年6月24日閲覧。

jrs.or.jp

“肺癌における免疫療法の新展開”. 日本呼吸器学会誌 3 (1): 46. (2014-01-24) 2015年7月9日閲覧。.

mayoclinic.org

“Mayo Researchers: Dramatic Outcomes in Prostate Cancer Study”. Mayo Clinic (2009年6月1日). 2009年6月24日閲覧。^{[リンク切れ]}

news-medical.net

“Phase 3 clinical study: Ipilimumab boosts, sustains immune system responses against melanoma tumors”. News-Medical.Net (2010年6月9日). 2011年3月25日閲覧。

nih.gov

pubmed.ncbi.nlm.nih.gov

Maverakis E, Cornelius LA, Bowen GM, Phan T, Patel FB, Fitzmaurice S, He Y, Burrall B, Duong C, Kloxin AM, Sultani H, Wilken R, Martinez SR, Patel F (2015). “Metastatic melanoma - a review of current and future treatment options”. Acta Derm Venereol 95 (5): 516-524. doi:10.2340/00015555-2035. PMID 25520039.
Ribas, Antoni; Hodi, F. Stephen; Callahan, Margaret; Konto, Cyril; Wolchok, Jedd (April 4, 2013). “Hepatotoxicity with combination of vemurafenib and ipilimumab”. N Engl J Med 368 (14): 1365-6. doi:10.1056/NEJMc1302338. PMID 23550685 2014年10月29日閲覧。.
Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S (2000). “Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.”. J Exp Med. 192 (2): 303-10. doi:10.1084/jem.192.2.303. PMC 2193248. PMID 10899917.
Tarhini AA, Iqbal F (2010). “CTLA-4 blockade: therapeutic potential in cancer treatments”. Onco Targets Ther 3: 15–25. doi:10.2147/ott.s4833. PMC 2895779. PMID 20616954.
Robert C, Ghiringhelli F (August 2009). “What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?”. Oncologist 14 (8): 848–61. doi:10.1634/theoncologist.2009-0028. PMID 19648604.
Tomillero A, Moral MA (October 2008). “Gateways to clinical trials”. Methods Find Exp Clin Pharmacol 30 (8): 643–72. PMID 19088949.
Poust J (December 2008). “Targeting metastatic melanoma”. Am J Health Syst Pharm 65 (24 Suppl 9): S9–S15. doi:10.2146/ajhp080461. PMID 19052265.
Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Golstein P. A new member of the immunoglobulin superfamily--CTLA-4. Nature. 1987 Jul 16-22;328(6127):267-70. PMID 3496540
Harper K, Balzano C, Rouvier E, Mattéi MG, Luciani MF, Golstein P. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J Immunol. 1991 Aug 1;147(3):1037-44. PMID 1713603

ncbi.nlm.nih.gov

Tarhini AA, Iqbal F (2010). “CTLA-4 blockade: therapeutic potential in cancer treatments”. Onco Targets Ther 3: 15–25. doi:10.2147/ott.s4833. PMC 2895779. PMID 20616954.
Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Golstein P. A new member of the immunoglobulin superfamily--CTLA-4. Nature. 1987 Jul 16-22;328(6127):267-70. PMID 3496540
Harper K, Balzano C, Rouvier E, Mattéi MG, Luciani MF, Golstein P. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J Immunol. 1991 Aug 1;147(3):1037-44. PMID 1713603

pmc.ncbi.nlm.nih.gov

Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S (2000). “Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.”. J Exp Med. 192 (2): 303-10. doi:10.1084/jem.192.2.303. PMC 2193248. PMID 10899917.
Tarhini AA, Iqbal F (2010). “CTLA-4 blockade: therapeutic potential in cancer treatments”. Onco Targets Ther 3: 15–25. doi:10.2147/ott.s4833. PMC 2895779. PMID 20616954.

nikkeibp.co.jp

medical.nikkeibp.co.jp

“欧州でも悪性黒色腫の治療薬としてイピリムマブが承認”. 日経メディカル (2011年7月20日). 2015年7月9日閲覧。

novapublishers.com

Lacroix, Marc (2014). Targeted Therapies in Cancer. Hauppauge , NY: Nova Sciences Publishers. ISBN 978-1-63321-687-7

nytimes.com

oclc.org

nejm.org.ucsf.idm.oclc.org

Ribas, Antoni; Hodi, F. Stephen; Callahan, Margaret; Konto, Cyril; Wolchok, Jedd (April 4, 2013). “Hepatotoxicity with combination of vemurafenib and ipilimumab”. N Engl J Med 368 (14): 1365-6. doi:10.1056/NEJMc1302338. PMID 23550685 2014年10月29日閲覧。.

peregrineinc.com

ir.peregrineinc.com

“Peregrine Pharmaceuticals Announces Initiation of an Investigator-Sponsored Trial Combining Its Immunotherapy Bavituximab and Ipilimumab (Yervoy) in Advanced Melanoma”. Peregrine Pharmaceuticals, Inc. 2015年7月9日閲覧。

pharmalot.com

Silverman E (2010年6月7日). “Bristol-Myers’ Melanoma Med And Wall Street Wags // Pharmalot”. Pharma Blog PHARMALOT. 2011年3月25日閲覧。^{[リンク切れ]}

reuters.com

rupress.org

jem.rupress.org

Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S (2000). “Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.”. J Exp Med. 192 (2): 303-10. doi:10.1084/jem.192.2.303. PMC 2193248. PMID 10899917.

sanofi.com.au

products.sanofi.com.au

“Arava (leflunomide) [package insert]”. Australia: Sanofi-Aventis, July 2014. 2014年11月2日閲覧。

sciencemag.org

Sharma, Pamanee; Allison, James P. (April 3, 2015). “The future of immune checkpoint therapy”. Science. doi:10.1126/science.aaa8172 2015年6月閲覧。エラー: 閲覧日は年・月・日のすべてを記入してください。.

web.archive.org

Langreth R (2010年6月6日). “The Risk For Bristol”. Science Business - research, innovation & policy. Forbes. 2011年7月22日時点のオリジナルよりアーカイブ。2011年3月25日閲覧。

webmd.com

Boyles S (2009年6月19日). “New Therapy May Fight Prostate Cancer”. WebMD. 2009年6月24日閲覧。

wikipedia.org

en.wikipedia.org

臨床試験番号 NCT00527735 - ClinicalTrials.gov Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)
臨床試験番号 NCT01524991 - ClinicalTrials.gov
臨床試験番号 NCT00323882 - ClinicalTrials.gov Phase I/II Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer (MDX010-21) (COMPLETED)